Moderna Stock News

Moderna surged on reports of talks with a large biopharma for a potential partnership or buyout, despite trading at multi-year lows. MRNA's promising cancer vaccine data and surprising findings on mRNA Covid vaccines boosting cancer survival rates drive renewed optimism for the drug pipeline. The company maintains a strong cash position, reduced costs, and a robust drug pipeline, with cancer va...

Shares of a social media juggernaut slumped as investors balked at its rapidly accelerating spending on artificial intelligence, while reports of potential partnership or buyout talks helped a vaccine maker's shares shoot higher.

When the S&P 500 is rallying to all-time highs, you have to wonder about the stocks getting left out. Turns out analysts see great promise.

CAMBRIDGE, MA / ACCESS Newswire / October 23, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked as a top employer in the global biopharmaceutical industry in Science and Science Careers' 2025 Top Employers Survey for the eleventh consecutive year. Moderna was recognized for its commitment to continuous innovation and a culture that reflects the values of its employees.

Moderna stock toppled Thursday after the biotech company's experimental CMV vaccine failed in a Phase 3 study of 7,500 women.

CAMBRIDGE, MA / ACCESS Newswire / October 23, 2025 / Moderna, Inc. (Nasdaq:MRNA) today announced that it will host its Investor Event - Analyst Day at 9:00 a.m. ET on Thursday, November 20, 2025.

Moderna said on Wednesday it will discontinue development of its experimental vaccine to prevent cytomegalovirus, a common cause of birth defects, after it failed to meet the main goal of a late-stage trial.

Company to discontinue development of mRNA-1647 in congenital CMV Company will continue to evaluate mRNA-1647 in ongoing Phase 2 trial in bone marrow transplant patients Company does not anticipate any impact to its 2025 financial guidance or its expectation of achieving breakeven in 2028 CAMBRIDGE, MA / ACCESS Newswire / October 22, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced topline re...